Healthcare Industry News: antiviral
News Release - January 31, 2007
Virabiotic's MolluscuDerm(TM) Topical Antiviral Therapy Launches at American Academy of Dermatology Meeting Feb. 2-5, 2007LAKE JESSAMINE, Fla.--(HSMN NewsFeed)--Virabiotics, Inc., announced today that their topical antiviral therapy, MolluscuDerm(TM), is being launched as a new product at the American Academy of Dermatology Annual Meeting in Washington, DC, February 2-5.
"MolluscuDerm is the first true topical antiviral treatment for Molluscum Contagiosum," said Dr. Gary Pekoe, President of Virabiotics. "MolluscuDerm represents a significant breakthrough in the treatment of Molluscum Contagiosum. We are enthused to be bringing it to the dermatologists at their most important meeting. The ability to launch the product at the AAD is a privilege and honor for the company, and we are excited that AAD has given us the opportunity to launch this exciting product."
Molluscum Contagiosum is a common infection in the United States and accounts for about 1% of all diagnosed skin disorders. Molluscum can occur in children and adults. Children, most commonly under five years of age, become infected through direct skin-to-skin contact or by touching objects contaminated with the Molluscum virus. In adults, Molluscum can be a sexually transmitted disease. It is estimated that 5% of children and up to 20% of AIDS patients have molluscum. Until the advent of MolluscuDerm, no effective topical treatment with proven antiviral capability has been available.
"As a practicing physician, I can testify to the true unmet need that MolluscuDerm fulfills," said Dr. Charles Shaffer, Chief Medical Officer for Virabiotics. "Because MolluscuDerm directly acts on the Molluscum virus, it begins working immediately to heal the lesions and clear the skin. We have had great patient responses to the use of the product, and are encouraged by the in vitro work that supports it."
MolluscuDerm is a proprietary blend of naturally occurring phytochemicals. A phytochemical is a non-nutrient plant product containing disease-fighting compounds. MolluscuDerm is marketed as a phytoceutical product via the internet and through selected specialty physician offices such as dermatologists.
Virabiotics, Inc. is a privately held Life Science company focused on the development and commercialization of novel topical products for the treatment of skin diseases including viral and bacterial skin infections.
For more information, or to order MolluscuDerm, visit our website at www.molluscuderm.com or call 1-866-321-2466.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.